查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995359

藥物研發服務市場：2026-2032年全球市場預測（依服務類型、技術、分子類型、最終用戶和治療領域分類）

Drug Discovery Services Market by Service Type, Technology, Molecule Type, End User, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物發現服務市場價值將達到 284.9 億美元，到 2026 年將成長至 327.3 億美元，到 2032 年將達到 760.9 億美元，複合年成長率為 15.06%。

主要市場統計數據
基準年 2025 284.9億美元
預計年份：2026年 327.3億美元
預測年份 2032 760.9億美元
複合年成長率 (%) 15.06%

本文說明了藥物發現服務產業的演變趨勢，重點在於能力融合、採購模式的演變以及影響轉化研究成功的營運挑戰。

藥物研發服務產業正經歷持續的變革，其驅動力來自技術進步的融合、合作模式的演變以及治療方法複雜性的日益增加。科學創新正朝著計算生物學、高通量實驗和客製化實驗室能力交叉融合的方向發展，服務供應商也透過拓展自身能力、整合新平台以及與申辦者建立更深入的夥伴關係來應對這項挑戰，從而降低轉化階段的風險。

一場技術和商業性變革正在透過人工智慧整合、自動化擴充性和合作研發夥伴關係模式來改變藥物發現服務。

產業正經歷一場變革性的轉變，這場轉變不僅重塑了科學研究的可能性範圍，也改變了商業性服務的交付方式。人工智慧 (AI) 和機器學習已從實驗輔助工具發展成為目標識別、解卷積和預測性 ADMET 評估的關鍵工具，使團隊能夠更精確地篩選化合物搜尋空間並確定實驗優先順序。同時，計算建模正日益融入整個工作流程，減少了後期階段對成本高昂的經驗篩檢的依賴。

評估 2025 年關稅措施對藥物研發服務供應商的供應鏈、採購慣例和資本規劃的累積營運和策略影響。

2025年實施的政策變化和關稅措施對供應鏈、籌資策略以及藥品配送服務的營運經濟產生了顯著的累積影響。對某些科學儀器、試劑和特殊組件徵收的額外關稅增加了依賴全球採購關鍵原料的供應商的接收成本。這促使許多機構重新評估其供應商所在地，盡可能將關鍵業務活動轉移到國內，並協商長期供應合約以穩定價格和供應。

將服務類型、底層技術、分子類別、最終用戶和治療領域與策略能力優先順序和差異化聯繫起來的詳細細分分析。

深入的細分分析揭示了差異化的服務線、技術平台、分子類別、終端用戶和治療領域如何創造獨特的競爭優勢和業務重點。就服務類型而言，ADME 和 DMPK 測試涵蓋生物分析服務、體外 ADME 和體內藥物動力學，每項都需要互補的儀器、嚴格的監管要求和資料管理實踐。生物標記發現包括基因生物標記、代謝組生物標記和蛋白質組生物標記物，每個子領域都需要獨特的樣本處理流程和分析流程。化合物合成和放大涵蓋客製化合成、GMP 生產和製程開發，其中製程可靠性和品質系統是區分市場領導的關鍵。先導化合物篩檢的範圍從片段篩檢和高內涵篩檢到高通量篩檢和虛擬篩檢，調查方法的選擇會影響後續的淘汰率和轉換相關性。先導藥物最適化整合了 ADMET 預測、計算化學、藥物化學和基於結構的藥物設計，需要跨學科合作。標靶辨識利用生物資訊學、基因組學、高內涵篩檢和蛋白質組學，將假設轉化為檢驗的標靶。毒性測試包括體外毒性測試、體內毒性測試和安全性藥理學，所有這些共同構成通往臨床開發的安全性保障。

全面的區域情報，說明了美洲、歐洲、中東和非洲以及亞太地區的商業性、監管和能力差異，這些差異影響著戰略部署。

區域趨勢影響策略定位、監管互動以及科學合作的步伐。了解這些差異對於設計服務部署和製定夥伴關係策略至關重要。在美洲，對綜合藥物研發能力的投資集中在大規模生物製藥中心和創新叢集周圍，這些區域接近性創業投資、學術機構和臨床網路，從而推動了對專業服務和快速轉化支援的需求。該地區的許多服務提供者強調端到端服務交付和先進的生物分析能力，以滿足申辦者對速度和數據品質的期望。

以平台廣度、專業領域知識和夥伴關係方式為重點的策略競爭分析，旨在確定公司在藥物發現服務領域的定位和差異化優勢。

主要企業之間的競爭格局體現在廣度、深度和專業化程度的趨同上，每家公司都採取不同的策略，力求在藥物研發的各個階段獲取價值。一些公司專注於平台廣度，建構涵蓋ADME（吸收、分佈、代謝和排泄）、生物標記發現、化合物合成和篩檢的整合平台，旨在為申辦者提供簡化的供應商管理，並確保整個研發階段的連續性。這些公司在標準化流程、資料互通性和法規遵循方面投入巨資，以滿足申辦方的複雜需求。

為行業領導者提供切實可行的建議，以加強數據管理實踐、實現供應鏈多元化、改進經營模式並投資跨學科人才，從而推動韌性和成長。

行業領導者應採取一系列即時和中期措施，以保持敏捷性並抓住藥物研發服務整體的新機會。首先，他們應優先投資於資料架構和互通性，將人工智慧和運算模型整合到整個工作流程中，同時確保可追溯性。互聯的資料環境可以減少重複工作，增強決策信心，並使申辦者能夠從以往的實驗中獲取價值。

結合專家訪談、技術檢驗和多方面證據整合的穩健混合調查方法，為可操作的行業洞察提供了支持。

本分析的調查方法結合了結構化的質性研究和嚴謹的證據整合，以確保結論的可操作性和合理性。主要研究包括對申辦方和提供方機構的高級研發負責人、採購負責人和實驗室主任進行深入訪談，以了解營運限制、技術採用的理由以及夥伴關係偏好。此外，還與計算生物學、生物分析和製程化學領域的專家進行了技術諮詢，以評估能力並檢驗新興技術趨勢。

摘要重點闡述了能力整合、供應鏈韌性和策略夥伴關係如何決定藥物研發服務的永續競爭優勢。

總之，藥物研發服務生態系統正處於策略轉折點，技術能力、經營模式創新和供應鏈韌性將共同決定其競爭成敗。隨著治療方法多樣化和轉化研究期望的提高，能夠將計算科學專長與高品質實驗平台相結合，並使自身商​​業提案與申辦方需求相契合的供應商，將更有利於獲取價值。政策變化和關稅趨勢凸顯了多元化供應鏈和彈性採購框架的必要性，而區域差異則要求制定有針對性的選址策略，以平衡成本、可及性和監管合規性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物研發服務市場：依服務類型分類

  • ADME/DMPK 測試
    • 生物分析服務
    • in vitro ADME
    • 體內藥物動力學
  • 生物標記發現
    • 基因生物標記
    • 代謝體學物標誌物
    • 蛋白質體學生物標記
  • 化合物的合成與放大
    • 客製合成
    • GMP生產
    • 製程開發
  • 命中篩檢
    • 片段篩檢
    • 高內涵篩檢
    • 高通量篩檢
    • 虛擬篩檢
  • 先導藥物最適化
    • ADMET預測
    • 計算化學
    • 藥物化學
    • 結構設計
  • 目標識別
    • 生物資訊學
    • 基因組學
    • 高內涵篩檢
    • 蛋白質體學
  • 毒性測試
    • 體外毒理學
    • 內分泌學
    • 安全藥理學

第9章：藥物發現服務市場：依技術分類

  • 計算生物學
    • 生物資訊學
    • 化學資訊學
    • 分子建模
  • 流式細胞技術
  • 高通量篩檢
    • 生化分析
    • 基於細胞的檢測
    • 無標定檢測
  • 質譜分析
  • 核磁共振
  • X光晶體結構分析

第10章：以分子類型分類的藥物發現服務市場

  • 生物製藥
  • 寡核苷酸
  • 胜肽
  • 低分子化合物

第11章 藥物發現服務市場：以最終用戶分類

  • 學術機構
  • 生技公司
  • CRO（受託研究機構）
  • 製藥公司

第12章 藥物研發服務市場：依治療領域分類

  • 心血管疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 代謝性疾病
  • 腫瘤學

第13章 藥物研發服務市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物發現服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物研發服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥物研發服務市場

第17章：中國藥物研發服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Charles River Laboratories International, Inc.
  • Drug Hunter Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • IQVIA Holdings Inc.
  • Labcorp.
  • Sai Life Sciences Limited
  • Syngene International Ltd.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Vipragen Biosciences Private Limited
Product Code: MRR-6611A511167C

The Drug Discovery Services Market was valued at USD 28.49 billion in 2025 and is projected to grow to USD 32.73 billion in 2026, with a CAGR of 15.06%, reaching USD 76.09 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.49 billion
Estimated Year [2026] USD 32.73 billion
Forecast Year [2032] USD 76.09 billion
CAGR (%) 15.06%

A focused introduction to the shifting drug discovery services landscape highlighting capability convergence, procurement evolution, and operational challenges affecting translational success

The drug discovery services landscape is undergoing a sustained period of transformation driven by converging technological advances, evolving collaboration models, and increasing complexity in therapeutic modalities. Scientific innovation now moves at the intersection of computational biology, high-throughput experimentation, and bespoke wet lab capabilities, and service providers are responding by broadening capabilities, integrating new platforms, and forming deeper partnerships with sponsors to de-risk translational steps.

Organizational decision-makers face intensified pressure to accelerate timelines while managing cost, data integrity, and regulatory expectations. In parallel, the rise of modular outsourcing models means sponsors can stitch together capabilities from distinct providers rather than rely on single large vendors, which necessitates improved coordination, standardized data exchange, and clarity on responsibility boundaries. These dynamics are reshaping procurement strategies and altering how value is assessed across service offerings.

Concurrently, human capital and specialized laboratory capacity remain critical bottlenecks. Firms that can blend computational proficiency with robust experimental validation are positioned to lead compound advancement from hit identification through lead optimization. This introduction frames the issues that follow and establishes the context for strategic choices about capability investment, partner selection, and risk mitigation that organizations must undertake to maintain competitive momentum.

Transformative technological and commercial shifts reshaping drug discovery services through AI integration, automation scalability, and collaborative R&D partnership models

The industry is experiencing transformative shifts that are remaking both what is possible scientifically and how services are delivered commercially. Artificial intelligence and machine learning have matured from experimental adjuncts to essential tools for target identification, deconvolution, and predictive ADMET assessment, enabling teams to triage chemical space and prioritize experiments with greater precision. At the same time, computational modeling is increasingly embedded across workflows, reducing reliance on costly empirical screens until later stages.

Laboratory automation and high-throughput screening platforms have accelerated throughput but also changed the value equation for physical assay design, pushing greater emphasis on assay fidelity and translational relevance. Simultaneously, advances in mass spectrometry, nuclear magnetic resonance, and single-cell technologies have improved sensitivity and depth of biological characterization, enabling richer biomarker discovery and mechanistic insight.

Commercial models are also shifting. Sponsors favor flexible, modular relationships rather than long exclusive contracts, and many service providers are evolving into collaborative R&D partners offering milestone-aligned engagements. Regulatory expectations are rising for traceability and data provenance, which elevates the importance of robust bioanalytical platforms and integrated data management. These cumulative shifts demand new governance, talent models, and investment priorities to capture the full potential of emergent technologies while preserving scientific rigor.

Assessment of the cumulative operational and strategic effects of 2025 tariff measures on supply chains, procurement practices, and capital planning across drug discovery service providers

Policy changes and tariff measures implemented in 2025 have had a notable cumulative impact on supply chains, procurement strategy, and the operational economics of drug discovery service delivery. Incremental duties on certain scientific equipment, reagents, and specialty components increased landed costs for providers that rely on global sourcing for critical inputs. This has prompted many organizations to reassess supplier footprints, bring critical activities onshore where feasible, and negotiate longer-term supply agreements to stabilize pricing and availability.

The tariffs also prompted a revaluation of capital planning. Providers that depend on imported instrumentation faced timing delays as procurement cycles adjusted to new cost realities and extended lead times. In response, some firms prioritized retrofitting existing capacity, investing in service optimization, or entering partnerships with domestic manufacturers to reduce exposure to cross-border policy volatility. Downstream, sponsors adapted by reallocating discretionary spend away from lower-priority exploratory campaigns toward activities that deliver higher translational value or by adopting more flexible contracting terms to share risk.

Beyond immediate cost effects, the broader consequence has been accelerated strategic localization and diversification of supplier networks. Organizations that proactively restructured procurement, strengthened inventory management, and invested in supply chain transparency were better positioned to maintain program continuity and protect timelines in the face of tariff-driven disruption.

Detailed segmentation insights linking service types, enabling technologies, molecule classes, end users, and therapeutic areas to strategic capability prioritization and differentiation

Insightful segmentation analysis reveals how differentiated service lines, technology platforms, molecule classes, end users, and therapeutic focuses create distinct competitive vectors and operational priorities. Within service type, ADME and DMPK testing spans bioanalytical services, in vitro ADME, and in vivo pharmacokinetics, each requiring complementary instrumentation, regulatory rigor, and data management practices. Biomarker discovery encompasses genomic biomarkers, metabolomic biomarkers, and proteomic biomarkers, with each subdomain demanding unique sample processing workflows and analytical pipelines. Compound synthesis and scale-up covers custom synthesis, GMP manufacturing, and process development, where process reliability and quality systems differentiate market leaders. Hit screening ranges from fragment screening and high content screening to high throughput and virtual screening, and the methodological choices here influence downstream attrition rates and translational relevance. Lead optimization integrates ADMET prediction, computational chemistry, medicinal chemistry, and structure-based design, necessitating cross-discipline collaboration. Target identification leverages bioinformatics, genomics, high content screening, and proteomics to move from hypothesis to validated targets. Toxicity testing includes in vitro toxicology, in vivo toxicology, and safety pharmacology, which together form the safety gate for clinical progression.

From a technology standpoint, computational biology, flow cytometry, high throughput screening, mass spectrometry, nuclear magnetic resonance, and X-ray crystallography form the core platforms. Computational biology subdivides into bioinformatics, cheminformatics, and molecular modeling, while high throughput screening incorporates biochemical assays, cell-based assays, and label-free assays, each with implications for throughput, sensitivity, and translational fidelity. Molecule type segmentation differentiates biologics, oligonucleotides, peptides, and small molecules, shaping development timelines, regulatory pathways, and required analytical capabilities. End users span academic institutions, biotechnology companies, contract research organizations, and pharmaceutical companies, each with distinct procurement behaviors and priorities. Therapeutic area focus across cardiovascular disorders, central nervous system disorders, infectious diseases, metabolic disorders, and oncology determines the assay endpoints, model systems, and biomarker strategies that services must support. Together, these segmentation layers inform where investments in specialization, platform integration, and talent should be directed to capture scientifically complex and commercially attractive opportunities.

Comprehensive regional intelligence describing commercial, regulatory, and capacity differentials across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape strategic footprints

Regional dynamics influence strategic positioning, regulatory engagement, and the cadence of scientific collaboration, and understanding these differences is essential for designing service footprints and partnership strategies. In the Americas, investment in integrated drug discovery capabilities is concentrated around large biopharma hubs and innovation clusters, where proximity to venture capital, academic centers, and clinical networks drives demand for specialized services and rapid translational support. Many providers in this region emphasize end-to-end offerings and advanced bioanalytical capabilities to meet sponsor expectations for speed and data quality.

In Europe, Middle East & Africa, the landscape is more heterogeneous, with centers of excellence in Western Europe complemented by emerging capabilities across other subregions. Regulatory harmonization efforts and collaborative public-private initiatives are shaping cross-border research programs, and service providers often differentiate through niche expertise, compliance depth, and regional partnerships that facilitate access to specific patient populations and unique scientific expertise.

Asia-Pacific has emerged as a capacity and innovation powerhouse, combining large contract research organization ecosystems with growing domestic biopharma R&D. Cost-competitive capabilities are maturing into higher-value services, and governments in several jurisdictions are actively supporting biotechnology expansion through incentives and infrastructure funding. Collectively, these regional profiles suggest that a geographically differentiated go-to-market approach-balancing proximity to sponsors, regulatory alignment, and cost structure-will be critical for providers seeking scalable, resilient operations.

Strategic competitive analysis emphasizing platform breadth, niche specialization, and partnership approaches that define company positioning and differentiation in discovery services

Competitive dynamics among leading companies are defined by a blend of breadth, depth, and specialization, with different players pursuing distinct strategies to capture value across the discovery continuum. Some firms focus on platform breadth, assembling integrated suites that span ADME, biomarker discovery, compound synthesis, and screening to offer sponsors simplified vendor management and continuity across development stages. These companies invest heavily in standardized processes, data interoperability, and regulatory compliance to meet complex sponsor requirements.

Other organizations pursue a strategy of deep specialization, concentrating on high-value niches such as advanced mass spectrometry, single-cell proteomics, or complex biologics process development, where technical excellence and reputational leadership command premium engagement models. A third cohort leverages computational strengths, combining bioinformatics, cheminformatics, and molecular modeling to accelerate target prioritization and design cycles. Across the industry, strategic partnerships, minority investments, and targeted mergers have created hybrid business models that blend in-house discovery with outsourced capacity.

Talent acquisition and retention are central competitive levers; firms that cultivate integrated teams of experimentalists, data scientists, and regulatory specialists deliver superior translational outcomes. Finally, service firms that can demonstrate reproducible data quality, transparent pricing models, and collaborative governance are most successful at converting single projects into long-term strategic relationships.

Actionable recommendations for industry leaders to strengthen data practices, diversify supply chains, evolve commercial models, and invest in interdisciplinary talent to drive resilience and growth

Industry leaders should pursue a set of immediate and medium-term actions to preserve agility and capture emerging opportunities across drug discovery services. First, prioritize investments in data architecture and interoperability so that AI and computational models can be embedded across workflows without sacrificing traceability. Linked data environments will reduce repetition, improve decision confidence, and enable sponsors to extract value from historical experiments.

Second, diversify supplier networks and build regional redundancy for critical reagents and equipment to mitigate policy and tariff volatility. This includes creating strategic inventory buffers, qualifying alternative sources, and negotiating flexible contracting terms that share risk between sponsors and providers. Third, develop hybrid commercial models that blend milestone-linked risk sharing with modular service offerings, enabling sponsors to scale engagement intensity up or down as portfolios evolve.

Fourth, invest in talent programs that bridge wet lab and computational skillsets, emphasizing cross-training, collaborative project structures, and clear career pathways to retain specialized staff. Fifth, forge selective partnerships with academic centers and technology developers to access emerging modalities while protecting core operational focus. Finally, embed regulatory engagement early in program design, particularly for complex biologics and oligonucleotide projects, to avoid late-stage surprises and ensure robust data packages for downstream development.

Robust mixed-methods research methodology combining expert interviews, technical validation, and multi-source evidence synthesis to underpin actionable industry insights

The research methodology underpinning this analysis combined structured qualitative inquiry with rigorous evidence synthesis to ensure conclusions are actionable and defensible. Primary research included in-depth interviews with senior R&D leaders, procurement officers, and laboratory directors across sponsor and provider organizations to surface operational constraints, technology adoption rationales, and partnership preferences. These interviews were complemented by technical consultations with subject matter experts in computational biology, bioanalytics, and process chemistry to validate capability assessments and emerging technology trajectories.

Secondary research drew on peer-reviewed literature, conference proceedings, regulatory guidance documents, and publicly disclosed technical white papers to build a baseline of factual context. The synthesis process involved triangulating insights across multiple sources, mapping capabilities to service segments and technologies, and stress-testing hypotheses through scenario analysis. Quality control measures included validation workshops with independent experts, cross-checking of technical assertions, and iterative review cycles to ensure clarity and accuracy.

Limitations were acknowledged where proprietary program details or recent transactions remained confidential, and the methodology emphasizes transparency about assumptions and data provenance to support informed decision-making by readers.

Concluding synthesis highlighting how capability integration, supply chain resilience, and strategic partnerships will determine sustained competitive advantage in discovery services

In conclusion, the drug discovery services ecosystem is at a strategic inflection point where technological capability, commercial model innovation, and supply chain resilience collectively determine competitive success. Providers that integrate computational expertise with high-quality experimental platforms, and that align their commercial propositions to sponsor needs, will be best positioned to capture value as therapeutic modalities diversify and translational expectations increase. Policy shifts and tariff dynamics underscore the need for supply chain diversification and flexible procurement frameworks, while regional differences demand targeted footprint strategies that balance cost, access, and regulatory alignment.

To translate insight into sustained advantage, organizations must execute on data modernization, talent development, and selective partnerships that expand capability without diluting focus. The synthesis presented here provides a structured basis for strategic choices about investments, collaborations, and operational redesign that will enable stakeholders to accelerate discovery, reduce avoidable risk, and preserve optionality as the scientific and commercial environment continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Services Market, by Service Type

  • 8.1. Adme Dmpk Testing
    • 8.1.1. Bioanalytical Services
    • 8.1.2. In Vitro Adme
    • 8.1.3. In Vivo Pharmacokinetics
  • 8.2. Biomarker Discovery
    • 8.2.1. Genomic Biomarkers
    • 8.2.2. Metabolomic Biomarkers
    • 8.2.3. Proteomic Biomarkers
  • 8.3. Compound Synthesis & Scale Up
    • 8.3.1. Custom Synthesis
    • 8.3.2. Gmp Manufacturing
    • 8.3.3. Process Development
  • 8.4. Hit Screening
    • 8.4.1. Fragment Screening
    • 8.4.2. High Content Screening
    • 8.4.3. High Throughput Screening
    • 8.4.4. Virtual Screening
  • 8.5. Lead Optimization
    • 8.5.1. Admet Prediction
    • 8.5.2. Computational Chemistry
    • 8.5.3. Medicinal Chemistry
    • 8.5.4. Structure Based Design
  • 8.6. Target Identification
    • 8.6.1. Bioinformatics
    • 8.6.2. Genomics
    • 8.6.3. High Content Screening
    • 8.6.4. Proteomics
  • 8.7. Toxicity Testing
    • 8.7.1. In Vitro Toxicology
    • 8.7.2. In Vivo Toxicology
    • 8.7.3. Safety Pharmacology

9. Drug Discovery Services Market, by Technology

  • 9.1. Computational Biology
    • 9.1.1. Bioinformatics
    • 9.1.2. Cheminformatics
    • 9.1.3. Molecular Modeling
  • 9.2. Flow Cytometry
  • 9.3. High Throughput Screening
    • 9.3.1. Biochemical Assays
    • 9.3.2. Cell Based Assays
    • 9.3.3. Label Free Assays
  • 9.4. Mass Spectrometry
  • 9.5. Nuclear Magnetic Resonance
  • 9.6. X Ray Crystallography

10. Drug Discovery Services Market, by Molecule Type

  • 10.1. Biologics
  • 10.2. Oligonucleotides
  • 10.3. Peptides
  • 10.4. Small Molecules

11. Drug Discovery Services Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. Drug Discovery Services Market, by Therapeutic Area

  • 12.1. Cardiovascular Disorders
  • 12.2. Central Nervous System Disorders
  • 12.3. Infectious Diseases
  • 12.4. Metabolic Disorders
  • 12.5. Oncology

13. Drug Discovery Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Discovery Services Market

17. China Drug Discovery Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Charles River Laboratories International, Inc.
  • 18.6. Drug Hunter Inc.
  • 18.7. Eurofins Scientific SE
  • 18.8. Evotec SE
  • 18.9. IQVIA Holdings Inc.
  • 18.10. Labcorp.
  • 18.11. Sai Life Sciences Limited
  • 18.12. Syngene International Ltd.
  • 18.13. TheraIndx Lifesciences Pvt. Ltd.
  • 18.14. Thermo Fisher Scientific Inc.
  • 18.15. Vipragen Biosciences Private Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO ADME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO ADME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO ADME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO PHARMACOKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO PHARMACOKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO PHARMACOKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GMP MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GMP MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GMP MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FRAGMENT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FRAGMENT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FRAGMENT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MEDICINAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MEDICINAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MEDICINAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH CONTENT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PROTEOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VITRO TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY IN VIVO TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SAFETY PHARMACOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SAFETY PHARMACOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SAFETY PHARMACOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CELL BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CELL BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CELL BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LABEL FREE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LABEL FREE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY LABEL FREE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY X RAY CRYSTALLOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY X RAY CRYSTALLOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY X RAY CRYSTALLOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY ADME DMPK TESTING, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPOUND SYNTHESIS & SCALE UP, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY HIT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARK